--- title: "Wall Street Zen Downgrades Cellectis (NASDAQ:CLLS) to Sell" description: "Wall Street Zen has downgraded Cellectis (NASDAQ:CLLS) from a \"hold\" to a \"sell\" rating. Barclays also reduced its price target for Cellectis from $5.00 to $4.00 while maintaining an \"overweight\" rati" type: "news" locale: "en" url: "https://longbridge.com/en/news/241716959.md" published_at: "2025-05-24T15:02:51.000Z" --- # Wall Street Zen Downgrades Cellectis (NASDAQ:CLLS) to Sell > Wall Street Zen has downgraded Cellectis (NASDAQ:CLLS) from a "hold" to a "sell" rating. Barclays also reduced its price target for Cellectis from $5.00 to $4.00 while maintaining an "overweight" rating. Cellectis shares traded up 0.3% to $1.53, with a market cap of $84.77 million. The company reported a quarterly EPS of ($0.18), missing estimates, and anticipates a fiscal year EPS of -0.46. Institutional investors hold 63.90% of the stock, indicating significant interest in the company. Cellectis (NASDAQ:CLLS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday. - Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal Separately, Barclays reduced their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. **Check Out Our Latest Stock Report on Cellectis** ## Cellectis Trading Up 0.3% Shares of NASDAQ:CLLS traded up $0.01 on Thursday, reaching $1.53. 6,779 shares of the company traded hands, compared to its average volume of 141,894. Cellectis has a 52 week low of $1.10 and a 52 week high of $2.95. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The business's 50-day simple moving average is $1.40 and its 200 day simple moving average is $1.58. The stock has a market capitalization of $84.77 million, a P/E ratio of -1.17 and a beta of 3.11. Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $12.03 million during the quarter, compared to the consensus estimate of $12.71 million. As a group, equities analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year. ## Institutional Inflows and Outflows Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. OLD Mission Capital LLC bought a new stake in Cellectis in the 1st quarter worth approximately $31,000. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. Acadian Asset Management LLC increased its position in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 26,461 shares during the last quarter. Millennium Management LLC purchased a new stake in Cellectis during the fourth quarter valued at $962,000. Finally, B Group Inc. purchased a new stake in Cellectis during the fourth quarter valued at $5,547,000. 63.90% of the stock is currently owned by institutional investors. ## About Cellectis (Get Free Report) Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. ## Featured Articles - Five stocks we like better than Cellectis - How to Profit From Growth Investing - 3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market - EV Stocks and How to Profit from Them - These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 - How to Plot Fibonacci Price Inflection Levels - Buy the Dip? 3 Oil Stocks Poised for a Big Comeback *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Cellectis Right Now? Before you consider Cellectis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list. While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CLLS.US - Cellectis](https://longbridge.com/en/quote/CLLS.US.md) - [BCS.US - Barclays](https://longbridge.com/en/quote/BCS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 彭博新聞報道，康菲石油正在考慮出售其價值 20 億美元的二疊紀資產 | 2 月 20 日（路透社）- 據彭博新聞週五報道，康菲石油正在探索出售其部分二疊紀盆地資產，這是其更廣泛的投資組合精簡的一部分，消息人士透露。這些資產是通過與 Concho Resources 和 Shell（SHEL.L）的交易在多年中收 | [Link](https://longbridge.com/en/news/276478732.md) | | 沃爾瑪四季度財報超預期但盈利指引不及預期，CEO 稱 “美國低收入家庭只能勉強維持生計” | 沃爾瑪 Q4 營收超預期，新財年盈利指引（每股 2.75-2.85 美元）遠低於市場預期的 2.96 美元，顯示通脹壓力下消費者支出不確定性猶存，拖累股價下跌 1.38%。財報印證 K 型” 分化：高收入家庭驅動增長，低收入羣體 “錢包吃緊 | [Link](https://longbridge.com/en/news/276398633.md) | | 學習英偉達刺激芯片銷售，AMD 為 “AI 雲” 借款做擔保 | AMD 為擴大市場份額祭出金融 “狠招”！為初創公司 Crusoe 的 3 億美元購芯貸款提供擔保，承諾在其無客户時 “兜底” 租用芯片。這一復刻英偉達 “租卡雲” 路徑的策略雖能短期推高銷量，但也令 AMD 在 AI 需求放緩時面臨更大的 | [Link](https://longbridge.com/en/news/276401504.md) | | 谷歌突然發佈 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌發佈了最新的大模型 Gemini 3.1 Pro，其推理性能較去年發佈的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 評測中，Gemini 3.1 Pro 得分 77.1%，顯示出強大的推理能力。新模型支持多源數據綜合和複雜 | [Link](https://longbridge.com/en/news/276396515.md) | | 最高法裁決後特朗普動用替補選擇：加徵 10% 全球關税 | 美國總統特朗普在最高法院裁決後宣佈將加徵 10% 的全球關税，以補救被推翻的關税措施。根據《1974 年貿易法》第 122 條款，現有的關税將全面生效。最高法院裁定特朗普政府的部分關税措施缺乏法律授權。市場風險提示，投資需謹慎。 | [Link](https://longbridge.com/en/news/276477629.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.